Cancer Policy FDA booth stood empty at 2025 ASCO annual meeting June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Cancer Policy ALT GOV: The HHS “resistance” on social media June 06, 2025Vol.51 No.22By Claire Marie Porter
Trials & Tribulations Surviving cancer is often not a patient’s most challenging battle May 30, 2025Vol.51 No.21By Boris C. Pasche
Cancer Policy A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration” May 30, 2025Vol.51 No.21By Jacquelyn Cobb
Cancer PolicyFree The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo May 23, 2025Vol.51 No.20
PodcastThe Directors The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear” May 16, 2025Vol.51 No.19By Katie Goldberg
Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.” May 16, 2025Vol.51 No.19By Jacquelyn Cobb
Guest Editorial An opportunity for Trump: Position U.S. cancer science to lead the world May 16, 2025Vol.51 No.19By Wafik S. El-Deiry
